Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Development of quantitative receptor-ligand binding assay for use as a tool to estimate immune responses against Plasmodium vivax Duffy binding protein Region II.

Shakri AR, Rizvi MM, Chitnis CE.

J Immunoassay Immunochem. 2012;33(4):403-13. doi: 10.1080/15321819.2012.659781.

PMID:
22963489
2.

Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.

Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, Pandey S, Chitnis CE, Chauhan VS.

Vaccine. 2007 Jul 9;25(28):5166-74. Epub 2007 May 21.

PMID:
17544179
3.

Production of recombinant PvDBPII, receptor binding domain of Plasmodium vivax Duffy binding protein, and evaluation of immunogenicity to identify an adjuvant formulation for vaccine development.

Bhardwaj R, Shakri AR, Hans D, Gupta P, Fernandez-Becerra C, Del Portillo HA, Pandey G, Chitnis CE.

Protein Expr Purif. 2017 Aug;136:52-57. doi: 10.1016/j.pep.2015.06.011. Epub 2015 Nov 11.

PMID:
26578115
4.

Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding protein.

Singh S, Pandey K, Chattopadhayay R, Yazdani SS, Lynn A, Bharadwaj A, Ranjan A, Chitnis C.

J Biol Chem. 2001 May 18;276(20):17111-6. Epub 2001 Mar 13.

5.

Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion.

Singh AP, Puri SK, Chitnis CE.

Mol Biochem Parasitol. 2002 Apr 30;121(1):21-31.

PMID:
11985860
6.

Targeting the Plasmodium vivax Duffy-binding protein.

Chitnis CE, Sharma A.

Trends Parasitol. 2008 Jan;24(1):29-34. Epub 2007 Nov 26. Review.

PMID:
18023618
7.

Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein.

Yazdani SS, Shakri AR, Mukherjee P, Baniwal SK, Chitnis CE.

Vaccine. 2004 Sep 9;22(27-28):3727-37.

PMID:
15315853
8.

Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys.

Arévalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R, Herrera S.

Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):25-31.

PMID:
16291763
9.

Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand.

Chootong P, Panichakul T, Permmongkol C, Barnes SJ, Udomsangpetch R, Adams JH.

PLoS One. 2012;7(4):e35769. doi: 10.1371/journal.pone.0035769. Epub 2012 Apr 27.

10.

Natural acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein (PvDBP-II) equally block erythrocyte binding of homologous and heterologous expressed PvDBP-II on the surface of COS-7 cells.

Valizadeh V, Zakeri S, Mehrizi AA, Mirkazemi S, Djadid ND.

Med Microbiol Immunol. 2016 Feb;205(1):85-95. doi: 10.1007/s00430-015-0429-7. Epub 2015 Aug 5.

PMID:
26243337
11.

Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection.

King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, Cole-Tobian JL, Mueller I, Chitnis CE.

Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8363-8. doi: 10.1073/pnas.0800371105. Epub 2008 Jun 3.

12.

Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion.

Hans D, Pattnaik P, Bhattacharyya A, Shakri AR, Yazdani SS, Sharma M, Choe H, Farzan M, Chitnis CE.

Mol Microbiol. 2005 Mar;55(5):1423-34.

13.

The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes.

Chitnis CE, Chaudhuri A, Horuk R, Pogo AO, Miller LH.

J Exp Med. 1996 Oct 1;184(4):1531-6.

14.

Immunization with recombinant duffy binding-like-gamma3 induces pan-reactive and adhesion-blocking antibodies against placental chondroitin sulfate A-binding Plasmodium falciparum parasites.

Costa FT, Fusaï T, Parzy D, Sterkers Y, Torrentino M, Douki JB, Traoré B, Petres S, Scherf A, Gysin J.

J Infect Dis. 2003 Jul 1;188(1):153-64. Epub 2003 Jun 23.

PMID:
12825185
15.

Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon Region.

Kano FS, Sanchez BA, Sousa TN, Tang ML, Saliba J, Oliveira FM, Nogueira PA, Gonçalves AQ, Fontes CJ, Soares IS, Brito CF, Rocha RS, Carvalho LH.

Trop Med Int Health. 2012 Aug;17(8):989-1000. doi: 10.1111/j.1365-3156.2012.03016.x. Epub 2012 May 30.

16.

Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.

Moreno A, Caro-Aguilar I, Yazdani SS, Shakri AR, Lapp S, Strobert E, McClure H, Chitnis CE, Galinski MR.

Vaccine. 2008 Aug 12;26(34):4338-44. doi: 10.1016/j.vaccine.2008.06.010. Epub 2008 Jun 23.

17.

Expression, purification and characterization of a functional region of the Plasmodium vivax Duffy binding protein.

Dutta S, Daugherty JR, Ware LA, Lanar DE, Ockenhouse CF.

Mol Biochem Parasitol. 2000 Jul;109(2):179-84. No abstract available.

PMID:
10960177
18.

The domain on the mouse Duffy protein for Plasmodium yoelii binding and invasion to mouse erythrocytes.

Xu L, Niu J, Chaudhuri A.

Mol Biochem Parasitol. 2006 Apr;146(2):142-50. Epub 2005 Dec 13.

PMID:
16386320
19.

Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies.

Pandey KC, Singh S, Pattnaik P, Pillai CR, Pillai U, Lynn A, Jain SK, Chitnis CE.

Mol Biochem Parasitol. 2002 Aug 7;123(1):23-33.

PMID:
12165386
20.

Fine specificity of Plasmodium vivax Duffy binding protein binding engagement of the Duffy antigen on human erythrocytes.

Siddiqui AA, Xainli J, Schloegel J, Carias L, Ntumngia F, Shoham M, Casey JL, Foley M, Adams JH, King CL.

Infect Immun. 2012 Aug;80(8):2920-8. doi: 10.1128/IAI.00206-12. Epub 2012 May 21. Retraction in: Infect Immun. 2015 Jun;83(6):2593.

Supplemental Content

Support Center